Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
-
Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at...
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
-
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved...
-
Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive...
-
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
-
Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported...
-
Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review...
-
MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the...